Huma won’t reverse split ya numb nuts 🔩
.
I do not think HUMA reverse splits.
As of June 25, 2026, HUMA is only about 6 trading days into the current sub-$1.00 streak.
They need 30 consecutive business days below $1.00 before a new Nasdaq deficiency notice would be triggered.
That means they still have about 24 more consecutive trading days before the notice even becomes an issue.
If the streak never breaks, the earliest 30-business-day mark is around July 30, 2026.
That means the earliest likely notice is late July or early August 2026.
After notice, Nasdaq generally gives 180 calendar days to regain compliance.
That pushes the practical deadline into late January 2027.
So the real question is not, “Will HUMA reverse split because it is under $1.00 today?”
The real question is, “Do you believe HUMA will still be stuck under $1.00 after getting through the next 6-plus months of catalysts?”
HUMA has to get through a massive catalyst window before Nasdaq pressure becomes a true forcing function.
During that window, they have:
Symvess commercial ramp already underway.
VA Strategic Acquisition Center contract already locked in.
Symvess now more accessible across roughly 170 VA hospitals.
DoD 1M+ in September from senate arms committee to study how to integrate it.
Saudi Arabia clinical evaluation and purchase commitment.
Potential Saudi JV or licensing partnership.
Israel Ministry of Health review process underway.
Dialysis Phase 3 V012 data already positive.
Dialysis sBLA planned for the second half of 2026.
CABG first-in-human study planned for July Aug September skipped phase 1 straight into phase2A making this a more realistic 4 product platform play with massive upside
PAD launching phase 3 trial in Oct, Nov, Dec. can sell partnership rights or just keep developing it for 3rd product PAD market is huge.
Fresh financing and cost cuts extending the runway through the key period.
That is the whole point.
They have not even triggered the new Nasdaq notice yet.
Even if they do, the cure window likely runs into late January 2027.
That means the company gets to go through VA, DoD, Saudi, Israel, dialysis sBLA, CABG, PAD, and Symvess commercialization before the reverse split becomes a real last-resort decision.
You do not voluntarily reverse split right before your first approved product has a chance to prove commercial demand.
You do not voluntarily reverse split right after locking in a federal procurement channel with the VA.
You do not voluntarily reverse split while military and DoD adoption is still developing.
You do not voluntarily reverse split while Saudi and Israel international expansion are still in motion.
You do not voluntarily reverse split before filing the dialysis sBLA.
You do not voluntarily reverse split when the dialysis opportunity connects directly to Fresenius, the world’s leading dialysis company and Humacyte’s key strategic partner.
You do not voluntarily reverse split while preparing CABG, which could open another massive vascular market.
You do not voluntarily reverse split while PAD remains another major platform shot on goal.
The smarter move is to let the catalyst calendar work.
Let VA access convert into orders.
Let DoD interest mature.
Let Saudi partnership talks play out.
Let Israel review progress.
Let the dialysis sBLA get filed.
Let Fresenius-related dialysis leverage matter.
Let CABG get marketing eyes in July / Aug
Let PAD launch phase 3
Let Symvess revenue ramp.
If all of that fails and the stock is still under $1.00 deep into the cure window, then yes, reverse split risk becomes real.
But that is not today’s setup.
Everyone is over reacting to the recent financing / final shakeout.